BRPI0409434A - formulações farmacêuticas nasais e métodos para usar as mesmas - Google Patents
formulações farmacêuticas nasais e métodos para usar as mesmasInfo
- Publication number
- BRPI0409434A BRPI0409434A BRPI0409434-4A BRPI0409434A BRPI0409434A BR PI0409434 A BRPI0409434 A BR PI0409434A BR PI0409434 A BRPI0409434 A BR PI0409434A BR PI0409434 A BRPI0409434 A BR PI0409434A
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical formulations
- drug substance
- methods
- formulations
- nasal pharmaceutical
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 3
- 229940088679 drug related substance Drugs 0.000 abstract 3
- 239000003246 corticosteroid Substances 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 239000007900 aqueous suspension Substances 0.000 abstract 1
- 229960001334 corticosteroids Drugs 0.000 abstract 1
- 229960002714 fluticasone Drugs 0.000 abstract 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 abstract 1
- 229960000289 fluticasone propionate Drugs 0.000 abstract 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical group C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 206010039083 rhinitis Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0029—Radiation
- A61L2/0035—Gamma radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
"FORMULAçõES FARMACêUTICAS NASAIS E MéTODOS PARA USAR AS MESMAS". A presente invenção refere-se a formulações farmacêuticas nasais descritas no presente relatório, que compreendem uma substância de droga com um perfil de distribuição de tamanhos de partículas específico. Esse perfil proporciona maior biodisponibilidade, maior eficácia ou efeito terapêutico prolongado da substância de droga quando administrada por via intranasal. As formulações da presente invenção podem compreender um ou mais corticoesteróides com um perfil de distribuição de tamanhos de partículas específico. Em uma modalidade preferida, o corticoesteróide é fluticasona ou um derivado farmaceuticamente aceitável da mesma para o tratamento de um ou mais sintomas de rinite. Preferivelmente, a substância de droga é propionato de fluticasona. As formulações do presente relatório podem ser administradas como uma suspensão aquosa apropriada para inalação por meio da via nasal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/414,756 US7811606B2 (en) | 2003-04-16 | 2003-04-16 | Nasal pharmaceutical formulations and methods of using the same |
PCT/EP2004/003315 WO2004091575A1 (en) | 2003-04-16 | 2004-03-29 | Nasal pharmaceutical formulations and methods of using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0409434A true BRPI0409434A (pt) | 2006-04-18 |
Family
ID=33158765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0409434-4A BRPI0409434A (pt) | 2003-04-16 | 2004-03-29 | formulações farmacêuticas nasais e métodos para usar as mesmas |
Country Status (14)
Country | Link |
---|---|
US (3) | US7811606B2 (pt) |
EP (1) | EP1613281B1 (pt) |
JP (1) | JP5403868B2 (pt) |
KR (1) | KR101312331B1 (pt) |
CN (1) | CN1805729B (pt) |
AU (1) | AU2004229148B8 (pt) |
BR (1) | BRPI0409434A (pt) |
CA (1) | CA2522291C (pt) |
ES (1) | ES2609910T3 (pt) |
HK (1) | HK1091727A1 (pt) |
MX (1) | MXPA05011105A (pt) |
RU (1) | RU2373925C2 (pt) |
WO (1) | WO2004091575A1 (pt) |
ZA (1) | ZA200509238B (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1605863B1 (en) * | 2003-03-14 | 2016-09-07 | Intersect ENT, Inc. | Sinus delivery of sustained release therapeutics |
US9808471B2 (en) * | 2003-04-16 | 2017-11-07 | Mylan Specialty Lp | Nasal pharmaceutical formulations and methods of using the same |
US8912174B2 (en) * | 2003-04-16 | 2014-12-16 | Mylan Pharmaceuticals Inc. | Formulations and methods for treating rhinosinusitis |
US7811606B2 (en) * | 2003-04-16 | 2010-10-12 | Dey, L.P. | Nasal pharmaceutical formulations and methods of using the same |
KR100675379B1 (ko) * | 2005-01-25 | 2007-01-29 | 삼성전자주식회사 | 프린팅 시스템 및 프린팅 방법 |
WO2006107957A2 (en) * | 2005-04-04 | 2006-10-12 | Sinexus, Inc. | Device and methods for treating paranasal sinus conditions |
US8535707B2 (en) * | 2006-07-10 | 2013-09-17 | Intersect Ent, Inc. | Devices and methods for delivering active agents to the osteomeatal complex |
EP2231065B8 (en) | 2007-12-18 | 2021-01-06 | Intersect ENT, Inc. | Self-expanding devices |
EP2320832A4 (en) | 2008-08-01 | 2015-07-29 | Intersect Ent Inc | METHODS AND DEVICES FOR CRIMPING SELF-DILATABLE DEVICES |
US7863074B2 (en) * | 2008-09-30 | 2011-01-04 | Stion Corporation | Patterning electrode materials free from berm structures for thin film photovoltaic cells |
WO2010132648A1 (en) * | 2009-05-15 | 2010-11-18 | Intersect Ent, Inc. | Expandable devices and methods therefor |
BR112013027391A2 (pt) * | 2011-05-03 | 2017-01-17 | Chiesi Farmaceutic S P A | formulação farmacêutica, frasco e kit |
DK2704687T3 (en) * | 2011-05-04 | 2015-10-05 | Chiesi Farma Spa | Topical formulation having a corticosteroid as an active ingredient |
AU2014236729B2 (en) | 2013-03-14 | 2018-11-22 | Intersect Ent, Inc. | Systems, devices, and method for treating a sinus condition |
US11554229B2 (en) | 2013-03-26 | 2023-01-17 | OptiNose Inc. | Nasal administration |
CN104940994B (zh) * | 2015-07-14 | 2017-09-19 | 江苏威克斯医疗科技有限公司 | 一种人造鼻粘膜及其用途 |
CN107320449B (zh) * | 2017-08-07 | 2020-09-15 | 武汉武药科技有限公司 | 丙酸氟替卡松鼻喷雾剂及其制备方法 |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3091569A (en) * | 1960-08-26 | 1963-05-28 | Mead Johnson & Co | Mucolytic-nu-acylated sulfhydryl compositions and process for treating animal mucus |
GB8432063D0 (en) * | 1984-12-19 | 1985-01-30 | Riker Laboratories Inc | Physically modified steroids |
EP0579260A1 (en) | 1987-07-07 | 1994-01-19 | Beecham Group Plc | Use of a vasodilator for the treatment of pulmonary hypertension and/or right heart failure-related conditions |
AU610175B2 (en) | 1988-05-25 | 1991-05-16 | Biogal Gyogyszergyar | Pharmaceutical composition comprising a compound containing sulfhydryl group(s) for the treatment of otitis |
CA2010894A1 (en) | 1989-02-28 | 1990-08-31 | Isamu Horikoshi | Method of forming a suspension and composition formed by said method |
JPH03165833A (ja) * | 1989-02-28 | 1991-07-17 | Isamu Horikoshi | 新規懸濁化方法及びこの方法によって得られる組成物 |
SE9000207L (sv) | 1990-01-22 | 1991-07-23 | Nobel Chemicals Ab | Laekemedel samt anvaendningen av detsamma |
MX9203396A (es) | 1990-09-10 | 1992-07-31 | Schering Corp | Monohidrato de furoato de mometasona, proceso para producirlo y composiciones farmaceuticas. |
US5177447A (en) * | 1990-11-06 | 1993-01-05 | Bear Automotive Service Equipment Company | Automated breakout box for automotive testing |
US5174475A (en) | 1991-03-26 | 1992-12-29 | Glaxo Inc. | Sequential dosing of antifungal and antiinflammatory compositions |
US5593688A (en) * | 1993-06-25 | 1997-01-14 | Nexstar Pharmaceuticals, Inc. | Liposomal targeting of ischemic tissue |
JPH0753358A (ja) | 1993-08-17 | 1995-02-28 | Teijin Ltd | 吸入剤 |
GB9410222D0 (en) * | 1994-05-21 | 1994-07-06 | Glaxo Wellcome Australia Ltd | Medicaments |
US6113894A (en) * | 1995-01-23 | 2000-09-05 | Smith; S. Gregory | Ophthalmic compositions and process of using |
IT1275955B1 (it) * | 1995-03-22 | 1997-10-24 | Dompe Spa | Formulazioni farmaceutiche in forma di gel tissotropico |
AU7106996A (en) | 1995-09-07 | 1997-03-27 | Fuisz Technologies Ltd. | System for rendering substantially non-dissoluble bio-affecting agents bio-available |
US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
US6576636B2 (en) * | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
US5976573A (en) * | 1996-07-03 | 1999-11-02 | Rorer Pharmaceutical Products Inc. | Aqueous-based pharmaceutical composition |
TW416953B (en) * | 1996-09-25 | 2001-01-01 | Takeda Chemical Industries Ltd | Tricyclic compounds for eliciting a prostaglandin I2 receptor agonistic effect, their production and use |
FR2756739B1 (fr) | 1996-12-05 | 2000-04-28 | Astra Ab | Nouvelle formulation de budesonide |
TW503113B (en) * | 1997-01-16 | 2002-09-21 | Senju Pharma Co | Aqueous suspension for nasal administration |
ES2172217T3 (es) | 1997-10-09 | 2002-09-16 | Schering Corp | Suspensiones de furoato de mometasona para nebulizacion. |
BR9814615A (pt) * | 1997-10-22 | 2001-10-16 | Jens Ponikau | Métodos e materiais para o tratamento e prevenção de inflamação do tecido da mucosa |
JP3386349B2 (ja) | 1997-10-30 | 2003-03-17 | 帝人株式会社 | 水性懸濁医薬品組成物 |
SE9704186D0 (sv) * | 1997-11-14 | 1997-11-14 | Astra Ab | New composition of matter |
US6423423B2 (en) * | 1998-05-06 | 2002-07-23 | Calsonic Kansei Corporation | Formed strip and roll forming |
US6241969B1 (en) * | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
DE69924504T2 (de) | 1998-08-26 | 2006-02-16 | Teijin Ltd. | Pulverförmige pernasale mittel |
IT1303692B1 (it) * | 1998-11-03 | 2001-02-23 | Chiesi Farma Spa | Procedimento per la preparazione di sospensioni di particelle difarmaci da somministrare per inalazione. |
US7521068B2 (en) | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
US20040141925A1 (en) * | 1998-11-12 | 2004-07-22 | Elan Pharma International Ltd. | Novel triamcinolone compositions |
US6521212B1 (en) | 1999-03-18 | 2003-02-18 | United Therapeutics Corporation | Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation |
KR100755798B1 (ko) * | 1999-06-03 | 2007-09-07 | 죤슨 앤 죤슨 컨슈머 프랑스 에스에이에스 | 화란국화(타나세텀 파르테니움) 추출물을 포함하는 국소 조성물과, 이 조성물을 사용해서 염증 질환을 치료 및 예방하는 방법 |
JP2001002589A (ja) * | 1999-06-18 | 2001-01-09 | Teijin Ltd | 穏やかな薬物血中濃度の上昇を可能とする経鼻投与用組成物 |
US20020061281A1 (en) * | 1999-07-06 | 2002-05-23 | Osbakken Robert S. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
AU6076200A (en) * | 1999-07-08 | 2001-01-30 | Johnson & Johnson Consumer Companies, Inc. | Exothermic bandage |
GB9918559D0 (en) | 1999-08-07 | 1999-10-06 | Glaxo Wellcome Kk | Novel pharmaceutical formulation |
WO2001013885A1 (en) | 1999-08-20 | 2001-03-01 | Norton Healthcare Ltd. | Method to produce powders for pulmonary or nasal administration |
GB9925934D0 (en) | 1999-11-03 | 1999-12-29 | Glaxo Group Ltd | Novel apparatus and process |
FI20002217A (fi) * | 1999-12-30 | 2001-07-01 | Orion Yhtymae Oyj | Inhalaatiopartikkelit |
GB0009605D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Medicaments |
US20020013331A1 (en) * | 2000-06-26 | 2002-01-31 | Williams Robert O. | Methods and compositions for treating pain of the mucous membrane |
GB0016040D0 (en) * | 2000-06-29 | 2000-08-23 | Glaxo Group Ltd | Novel process for preparing crystalline particles |
KR20030023700A (ko) * | 2000-07-14 | 2003-03-19 | 알러간, 인코포레이티드 | 치료활성 성분을 함유하고 용해도가 증강된 조성물 |
US6608054B2 (en) * | 2001-03-20 | 2003-08-19 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics and endothelin antagonists |
WO2002055136A2 (en) | 2000-12-01 | 2002-07-18 | Nephros Therapeutics Inc | Intrasvascular drug delivery device and use therefor |
DE10060890C2 (de) * | 2000-12-07 | 2003-04-03 | Meta Motoren Energietech | Vorrichtung zum Umschalten des Betriebs eines Ladungswechselventils einer Brennkraftmaschine |
CA2441854A1 (en) * | 2001-02-05 | 2002-09-19 | Pharmacia & Upjohn Company | Composition for rectal delivery of an oxazolidinone antibacterial drug |
GB0105560D0 (en) * | 2001-03-07 | 2001-04-25 | Glaxo Group Ltd | Pharmaceutical formulations |
AU2002303164A1 (en) * | 2001-03-23 | 2002-10-08 | Protarga, Inc. | Fatty amine drug conjugates |
ES2387562T3 (es) * | 2001-03-23 | 2012-09-26 | Luitpold Pharmaceuticals, Inc. | Conjugados alcohol graso-medicamento |
US20020198209A1 (en) * | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Compositions having enhanced pharmacokinetic characteristics |
US20030040509A1 (en) | 2001-08-06 | 2003-02-27 | Genomed, Llc | Methods and compositions for treating diseases associated with excesses in ACE |
FR2831446B1 (fr) | 2001-10-26 | 2004-03-05 | Sanofi Synthelabo | Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire |
ITMI20022674A1 (it) * | 2002-12-18 | 2004-06-19 | Chiesi Farma Spa | Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione. |
US9808471B2 (en) * | 2003-04-16 | 2017-11-07 | Mylan Specialty Lp | Nasal pharmaceutical formulations and methods of using the same |
US7811606B2 (en) * | 2003-04-16 | 2010-10-12 | Dey, L.P. | Nasal pharmaceutical formulations and methods of using the same |
-
2003
- 2003-04-16 US US10/414,756 patent/US7811606B2/en active Active
-
2004
- 2004-03-29 ES ES04724015.5T patent/ES2609910T3/es not_active Expired - Lifetime
- 2004-03-29 KR KR1020057019609A patent/KR101312331B1/ko active IP Right Grant
- 2004-03-29 CA CA2522291A patent/CA2522291C/en not_active Expired - Lifetime
- 2004-03-29 JP JP2006504901A patent/JP5403868B2/ja not_active Expired - Lifetime
- 2004-03-29 EP EP04724015.5A patent/EP1613281B1/en not_active Expired - Lifetime
- 2004-03-29 CN CN2004800166459A patent/CN1805729B/zh not_active Expired - Lifetime
- 2004-03-29 RU RU2005135332/15A patent/RU2373925C2/ru active
- 2004-03-29 AU AU2004229148A patent/AU2004229148B8/en not_active Expired
- 2004-03-29 BR BRPI0409434-4A patent/BRPI0409434A/pt not_active Application Discontinuation
- 2004-03-29 WO PCT/EP2004/003315 patent/WO2004091575A1/en active Application Filing
- 2004-03-29 MX MXPA05011105A patent/MXPA05011105A/es active IP Right Grant
-
2005
- 2005-10-14 US US11/250,256 patent/US7972627B2/en not_active Expired - Lifetime
- 2005-11-15 ZA ZA200509238A patent/ZA200509238B/en unknown
-
2006
- 2006-11-08 HK HK06112257.7A patent/HK1091727A1/xx not_active IP Right Cessation
-
2007
- 2007-10-31 US US11/931,424 patent/US8158154B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
KR20060003009A (ko) | 2006-01-09 |
ES2609910T3 (es) | 2017-04-25 |
HK1091727A1 (en) | 2007-01-26 |
JP5403868B2 (ja) | 2014-01-29 |
AU2004229148B8 (en) | 2010-12-02 |
AU2004229148A1 (en) | 2004-10-28 |
AU2004229148B2 (en) | 2010-11-25 |
CN1805729B (zh) | 2010-09-22 |
CA2522291C (en) | 2011-12-06 |
WO2004091575A1 (en) | 2004-10-28 |
RU2005135332A (ru) | 2006-08-10 |
MXPA05011105A (es) | 2006-05-19 |
US8158154B2 (en) | 2012-04-17 |
EP1613281B1 (en) | 2016-10-05 |
US7972627B2 (en) | 2011-07-05 |
US20060039871A1 (en) | 2006-02-23 |
US7811606B2 (en) | 2010-10-12 |
ZA200509238B (en) | 2007-04-25 |
CA2522291A1 (en) | 2004-10-28 |
JP2006523629A (ja) | 2006-10-19 |
US20080058295A1 (en) | 2008-03-06 |
KR101312331B1 (ko) | 2013-09-27 |
CN1805729A (zh) | 2006-07-19 |
US20040208831A1 (en) | 2004-10-21 |
RU2373925C2 (ru) | 2009-11-27 |
EP1613281A1 (en) | 2006-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0409381A (pt) | formulações farmacêuticas nasais e métodos de utilizar as mesmas | |
BRPI0409434A (pt) | formulações farmacêuticas nasais e métodos para usar as mesmas | |
Pires et al. | Intranasal drug delivery: how, why and what for? | |
Martins et al. | Strategies to facilitate or block nose-to-brain drug delivery | |
ES2876350T3 (es) | Métodos para aumentar la inhibición tónica y tratamiento del insomnio secundario | |
BRPI0507609A (pt) | combinações terapêuticas de anti-psicóticos atìpicos com antagonistas de fator de liberação de corticotropina | |
CA2756690C (en) | Administration of benzodiazepine compositions | |
WO2006122318A3 (en) | Directed intranasal administration of pharmaceutical agents | |
BRPI0312128B8 (pt) | formulação farmacêutica compreendendo azelastina e éster de fluticasona | |
US6297227B1 (en) | Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines | |
AR026610A1 (es) | Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central | |
BRPI0508170A (pt) | formulações farmacêuticas para inaladores de pó seco, que compreendem um ingrediente ativo de potência de baixa dosagem | |
CA2474479A1 (en) | Composition for inhalation | |
Alkotaji | Azithromycin and ambroxol as potential pharmacotherapy for SARS-CoV-2 | |
JP2019530751A (ja) | 神経変性疾患を処置するためのカンナビノイド含有複合混合物 | |
EA200800007A1 (ru) | Фармацевтические композиции на основе нейроактивного стероида и их применение | |
BRPI0519030A2 (pt) | mÉtodos de tratamento, prevenÇço, ou controle de inflamaÇço das vias aÉreas e de uma doenÇa ou distérbio das vias aÉreas ou pulmonar, e, composiÇço farmacÊutica | |
CA2671470A1 (en) | Powder formulation for valganciclovir | |
PT1256339E (pt) | Sistema terapeutico transdermico para doenca de parkinson que induz niveis plasmaticos altos de rotigotina | |
BRPI0304821B8 (pt) | processo de preparação de uma suspensão estéril de partículas de corticosteróide para administração por inalação | |
MY159377A (en) | Aqueous suspensions of ciclesonide for nebulisation | |
CL2016001707A1 (es) | Tratamiento de trastornos congnitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma (div. sol. 1178-11). | |
ES2426957T3 (es) | Procedimiento de tratamiento de rinosinusitis aguda | |
PE20011049A1 (es) | Combinacion de farmacos para el tratamiento de la depresion y trastornos relacionados que comprenden mirtazapina | |
ATE326947T1 (de) | Thixotropes nasenspray |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: MYLAN, INC. (US) |
|
B25A | Requested transfer of rights approved |
Owner name: MYLAN SPECIALITY L.P. (US) |